Biostage raises $2.6M in private placements, appoints Jerry He to board

Harvard Apparatus Regenerative Technology, Inc.

Raised $2.0M in Sept 2021 from DST Capital and An Zhang in private placement of 1M shares and warrants for 500K shares at $2.00 per unit.
Combined with $0.6M from earlier placements in May/June 2021, total cash infusion of $2.6M.
Proceeds expected to fund operations and capex into Q4 2021.
Appointed Jerry He (Executive Vice Chairman of Bright Scholar) as Class I independent director; options worth $25K + annual cash fees $20K.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Junli He

Class I director

HRGN · Harvard Apparatus Regenerative Technology, Inc.

Effective: 2021-09-01
Filed: September 8, 2021, 7:59 PM ET

On September 1, 2021, Junli He, the Executive Vice Chairman of Bright Scholar Holdings, joined the Board of Directors (the “Board”) of the Company as a Class I director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Junli He was appointed as Class I director at Harvard Apparatus Regenerative Technology, Inc..

Action: joined the Board
Role: Class I director

Exact text from the filing

On September 1, 2021, Junli He, the Executive Vice Chairman of Bright Scholar Holdings, joined the Board of Directors (the “Board”) of the Company as a Class I director.

View on SEC.gov

Harvard Apparatus Regenerative Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-113653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.